A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling

BACKGROUND: TGFβ1 is a major profibrotic mediator in chronic kidney disease (CKD). Its direct inhibition, however, is limited by adverse effects. Inhibition of activins, also members of the TGFβ superfamily, blocks TGFβ1 profibrotic effects, but the mechanism underlying this and the specific activin...

Descripción completa

Detalles Bibliográficos
Autores principales: Soomro, Asfia, Khajehei, Mohammad, Li, Renzhong, O’Neil, Kian, Zhang, Dan, Gao, Bo, MacDonald, Melissa, Kakoki, Masao, Krepinsky, Joan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885651/
https://www.ncbi.nlm.nih.gov/pubmed/36717814
http://dx.doi.org/10.1186/s11658-023-00424-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885651/
https://www.ncbi.nlm.nih.gov/pubmed/36717814
http://dx.doi.org/10.1186/s11658-023-00424-1

Ejemplares similares